会員登録
ログイン
【4890】坪田ラボ
近視、ドライアイ、老眼等の治療に係る医薬品、医療機器等の研究開発
売上高
営業利益
経常利益
当期利益
{{models[key].tabname}}
| 決算期 | 日付 | 予・実 | 売上高 (百万円) |
対前回 | 修正率 | 修正率 | 営業利益 (百万円) |
対前回 | 修正率 | 修正率 | 経常利益 (百万円) |
対前回 | 修正率 | 修正率 | 当期利益 (百万円) |
対前回 | 修正率 | 修正率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026.03 | 2025/11/11 | Q2予 | 1,400 | → | 0.0% | 0.0% | 200 | → | 0.0% | 0.0% | 220 | → | 0.0% | 0.0% | 150 | → | 0.0% | 0.0% |
| 2026.03 | 2025/08/06 | Q1予 | 1,400 | → | 0.0% | 0.0% | 200 | → | 0.0% | 0.0% | 220 | → | 0.0% | 0.0% | 150 | → | 0.0% | 0.0% |
| 2026.03 | 2025/05/12 | 当初予 | 1,400 | - | - | - | 200 | - | - | - | 220 | - | - | - | 150 | - | - | - |
| 2025.03 | 2025/05/12 | 実 | 1,357 | ↑ | +0.5% | +13.1% | 235 | ↓ | -9.6% | +79.4% | 281 | ↓ | -6.3% | +116.2% | 205 | ↑ | +2.5% | +105.0% |
| 2025.03 | 2025/04/21 | 修正予 | 1,350 | ↑ | +12.5% | +12.5% | 260 | ↑ | +98.5% | +98.5% | 300 | ↑ | +87.5% | +130.8% | 200 | ↑ | +81.8% | +100.0% |
| 2025.03 | 2025/02/12 | Q3予 | 1,200 | → | 0.0% | 0.0% | 131 | → | 0.0% | 0.0% | 160 | ↑ | +23.1% | +23.1% | 110 | ↑ | +10.0% | +10.0% |
| 2025.03 | 2024/11/12 | Q2予 | 1,200 | → | 0.0% | 0.0% | 131 | → | 0.0% | 0.0% | 130 | → | 0.0% | 0.0% | 100 | → | 0.0% | 0.0% |
| 2025.03 | 2024/08/13 | Q1予 | 1,200 | → | 0.0% | 0.0% | 131 | → | 0.0% | 0.0% | 130 | → | 0.0% | 0.0% | 100 | → | 0.0% | 0.0% |
| 2025.03 | 2024/05/13 | 当初予 | 1,200 | - | - | - | 131 | - | - | - | 130 | - | - | - | 100 | - | - | - |
| 2024.03 | 2024/05/13 | 実 | 673 | ↓ | -2.2% | -35.2% | -649 | ↑ | +4.6% | -2193.5% | -636 | ↑ | +5.8% | -2220.0% | -641 | ↑ | +5.7% | -3305.0% |
| 2024.03 | 2024/03/07 | 修正予 | 688 | ↑ | +189.1% | -33.8% | -680 | ↑ | +39.8% | -2293.5% | -675 | ↑ | +40.0% | -2350.0% | -680 | ↑ | +39.8% | -3500.0% |
| 2024.03 | 2024/02/13 | Q3予 | 238 | → | 0.0% | -77.1% | -1,130 | → | 0.0% | -3745.2% | -1,125 | → | 0.0% | -3850.0% | -1,130 | → | 0.0% | -5750.0% |
| 2024.03 | 2024/02/08 | 修正予 | 238 | ↓ | -77.1% | -77.1% | -1,130 | ↓ | -3745.2% | -3745.2% | -1,125 | ↓ | -3850.0% | -3850.0% | -1,130 | ↓ | -5750.0% | -5750.0% |
| 2024.03 | 2023/11/10 | Q2予 | 1,039 | → | 0.0% | 0.0% | 31 | → | 0.0% | 0.0% | 30 | → | 0.0% | 0.0% | 20 | → | 0.0% | 0.0% |
| 2024.03 | 2023/08/10 | Q1予 | 1,039 | → | 0.0% | 0.0% | 31 | → | 0.0% | 0.0% | 30 | → | 0.0% | 0.0% | 20 | → | 0.0% | 0.0% |
| 2024.03 | 2023/05/12 | 当初予 | 1,039 | - | - | - | 31 | - | - | - | 30 | - | - | - | 20 | - | - | - |
| 2023.03 | 2023/05/12 | 実 | 954 | ↓ | -0.1% | -25.4% | 167 | ↓ | -10.7% | -36.3% | 144 | ↓ | -12.2% | -45.0% | 90 | ↓ | -16.7% | -50.3% |
| 2023.03 | 2023/03/29 | 修正予 | 955 | ↓ | -25.3% | -25.3% | 187 | ↓ | -28.6% | -28.6% | 164 | ↓ | -37.4% | -37.4% | 108 | ↓ | -40.3% | -40.3% |
| 2023.03 | 2023/02/10 | Q3予 | 1,278 | → | 0.0% | 0.0% | 262 | → | 0.0% | 0.0% | 262 | → | 0.0% | 0.0% | 181 | → | 0.0% | 0.0% |
| 2023.03 | 2022/11/10 | Q2予 | 1,278 | → | 0.0% | 0.0% | 262 | → | 0.0% | 0.0% | 262 | → | 0.0% | 0.0% | 181 | → | 0.0% | 0.0% |
| 2023.03 | 2022/08/12 | 当初予 | 1,278 | - | - | - | 262 | - | - | - | 262 | - | - | - | 181 | - | - | - |
